Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
JAZZ
$244.96
-0.36%
JAZZ · Jazz Pharmaceuticals plc
$244.96
-0.89 (-0.36%)
At close · Aug 14
Market Cap
$15.90B
Shares
64.91M
All earnings calls
Earnings call · FY2026 Q2
Q2 2026 Jazz Pharmaceuticals Earnings Conference Call
Q2 2026 Jazz Pharmaceuticals Earnings Conference Call
Forward guidance
9 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Revenue
$1.21B
+15.5% YoY
Diluted EPS
$2.78
Net income
$192.80M
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 3, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total Revenues
full-year 2026
|
$4.6B – $4.75B | — | |
|
Gross margin %
table
full-year 2026
|
89% – 90% | GAAP | |
|
SG&A expenses
table
full-year 2026
|
$1.51B – $1.56B | GAAP | |
|
Effective tax rate
table
full-year 2026
|
0% – 10% | GAAP | |
|
R&D expenses
table
full-year 2026
|
$818M – $873M | GAAP | |
|
SG&A expenses
table
full-year 2026
|
$1.33B – $1.37B | Non-GAAP | |
|
Gross margin %
table
full-year 2026
|
90% – 91% | Non-GAAP | |
|
Effective tax rate
table
full-year 2026
|
11.5% – 13.5% | Non-GAAP | |
|
R&D expenses
table
full-year 2026
|
$725M – $775M | Non-GAAP |
Quarter detail
How the reported period landed and where the business moved.
SEC filing · Item 2.02
8-K earnings release
Filed Aug 3, 2026 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 3, 2026 · complete as-filed document